Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) and Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership and valuation.
Institutional and Insider Ownership
95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are owned by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are owned by insiders. Comparatively, 7.1% of Abeona Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Volatility & Risk
Amylyx Pharmaceuticals has a beta of -0.09, suggesting that its share price is 109% less volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500.
Profitability
This table compares Amylyx Pharmaceuticals and Abeona Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Amylyx Pharmaceuticals | N/A | -41.54% | -38.91% |
| Abeona Therapeutics | -160.30% | -44.82% | -32.51% |
Analyst Recommendations
This is a summary of recent ratings for Amylyx Pharmaceuticals and Abeona Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Amylyx Pharmaceuticals | 1 | 0 | 6 | 2 | 3.00 |
| Abeona Therapeutics | 1 | 0 | 5 | 0 | 2.67 |
Amylyx Pharmaceuticals currently has a consensus target price of $43.71, suggesting a potential upside of 49.27%. Abeona Therapeutics has a consensus target price of $21.00, suggesting a potential upside of 733.33%. Given Abeona Therapeutics’ higher probable upside, analysts clearly believe Abeona Therapeutics is more favorable than Amylyx Pharmaceuticals.
Valuation & Earnings
This table compares Amylyx Pharmaceuticals and Abeona Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Amylyx Pharmaceuticals | N/A | N/A | -$144.74 million | ($1.44) | -20.34 |
| Abeona Therapeutics | $5.82 million | 24.75 | $71.18 million | ($1.07) | -2.36 |
Abeona Therapeutics has higher revenue and earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.
About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.
About Abeona Therapeutics
Abeona Therapeutics, Inc. is a biotechnology company focused on developing cell and gene therapies for serious and rare diseases. Its work includes treatments designed to address the underlying genetic causes of disease. The company’s lead product, ZEVASKYN (prademagene zamikeracel), is an autologous gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, a rare inherited skin disorder. Made from a patient’s skin cells, the therapy uses genetic modification to help cells produce type VII collagen and is applied to wounds.
Receive News & Ratings for Amylyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amylyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
